SCHEMBL4381073

SCHEMBL4381073

Cn1cnc(N)nc1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14580329 0.79 — —
SCHEMBL12724275 0.77 CDK1 (0.47) —
SCHEMBL17040215 0.74 — —
SCHEMBL506099 0.74 DNMT1 (0.39) —
SCHEMBL1666675 0.73 — —
SCHEMBL12451367 0.72 CDK1 (0.47) —
SCHEMBL12702629 0.72 ALDH1A1 (0.44) —
SCHEMBL5694084 0.71 DNMT1 (0.37) —
SCHEMBL25065522 0.70 ADORA2A (0.36) —
SCHEMBL24248823 0.70 GDA (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220428-A1 COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 — — WO disclosed
WO-2023220440-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-11-16 — — WO disclosed
WO-2023178133-A9 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-10-26 — — WO disclosed
WO-2023178133-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS, INC. (US) 2023-09-21 — — WO disclosed
WO-2022219636-A1 ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS, AND USES THEREOF YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2022-10-20 — — WO disclosed
US-20220298185-A1 Nucleoside Prodrugs and Uses Related Thereto UNIV EMORY (US) 2022-09-22 — — US disclosed
EP-2970358-B1 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS LLC (US) 2021-06-30 — — EP disclosed
EP-2970359-B1 FLUORINATED PYRIMIDINE ANALOGS AND METHODS OF USE THEREOF EPIGENETICS PHARMA LLC (US) 2021-04-07 — — EP disclosed
WO-2021034373-A1 CONJUGATES OF GUIDE RNA-CAS PROTEIN COMPLEX ZHONG MINGHONG (US) 2021-02-25 — — WO disclosed
US-20210054371-A1 Conjugates of Guide RNA-Cas Protein Complex ZHONG MINGHONG (US) 2021-02-25 — — US disclosed
US-20100056771-A1 Process of Making 2-Deoxy-2,2-Difluoro-D-Ribofuranosyl Nucleosides and Intermediates Therefor SCINOPHARM TAIWAN LTD. (TW) 2010-03-04 — — US disclosed
US-20100016252-A1 Mannich Base N-Oxide Drugs State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) 2010-01-21 — — US disclosed
US-7598246-B2 Bisphosphonate conjugates and methods of making and using the same MBC PHARMA, INC. (US) 2009-10-06 — — US disclosed
US-7598246-B2 Bisphosphonate conjugates and methods of making and using the same MBC PHARMA, INC. (US) 2009-10-06 — — US disclosed
US-20080293651-A1 CYTOSINE NUCLEOSIDE ANALOGS AND ISOFLAVONES AND USES THEREOF INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) 2008-11-27 — — US disclosed
WO-2008118852-A1 METHOD FOR TREATING AND PREVENTING ARTHRITIS SOUTHERN RESEARCH INSTITUTE (US) 2008-10-02 — — WO disclosed
US-20080139566-A1 SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF HOWELL AMY R 2008-06-12 — — US disclosed
US-20080139566-A1 SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF HOWELL AMY R 2008-06-12 — — US disclosed
US-7351827-B2 Substituted oxetanes, method of making, and method of use thereof THE UNIVERSITY OF CONNECTICUT (US) 2008-04-01 — — US disclosed
US-7351827-B2 Substituted oxetanes, method of making, and method of use thereof THE UNIVERSITY OF CONNECTICUT (US) 2008-04-01 — — US disclosed
Send feedback